Who owns ONCOCYTE CORPORATION COM?
- Ticker: IMDX
- CUSIP Number: 68235c206
Tip: Access positions for across all investors
Analyze quarterly positions in Oncocyte Corporation with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Oncocyte Corporation stock
Who bought or sold ONCOCYTE CORPORATION COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Broadwood Capital | 11M | $86M | 0% | Dec 2025 |
|
| AWM Investment Company | 2.8M | $9.2M | 0% | Mar 2026 |
|
| Pura Vida Investments | 947k | $3.1M | 0% | Mar 2026 |
|
| Alyeska Investment Group | 841k | $2.8M | 100% | Mar 2026 |
|
| Vanguard Capital Management | 537k | $1.8M | 100% | Mar 2026 |
|
| Vanguard Group | 527k | $4.0M | 8% | Dec 2025 |
|
| Geode Capital Management | 262k | $860k | 13% | Mar 2026 |
|
| FNY Investment Advisers | 247k | $811k | 510% | Mar 2026 |
|
| BlackRock | 135k | $444k | 3% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 133k | $435k | 100% | Mar 2026 |
|
| Family Office Research | 127k | $417k | 100% | Mar 2026 |
|
| Millennium Management | 104k | $339k | 69% | Mar 2026 |
|
| Susquehanna International | 73k | $543k | 100% | Dec 2025 |
|
| Ghisallo Capital Management | 71k | $232k | 100% | Mar 2026 |
|
| Northern Trust | 49k | $366k | 49% | Dec 2025 |
|
| State Street Corporation | 48k | $358k | 14% | Dec 2025 |
|
| Morgan Stanley | 36k | $118k | 0% | Mar 2026 |
|
| 683 Capital Management | 29k | $95k | -62% | Mar 2026 |
|
| Qube Research & Technologies | 28k | $213k | 100% | Dec 2025 |
|
| Advisor Group Holdings | 24k | $181k | 115% | Dec 2025 |
|
| UBS Group | 23k | $75k | 674% | Mar 2026 |
|
| Renaissance Technologies | 13k | $101k | -43% | Dec 2025 |
|
| Flatrock Wealth Partners | 13k | $43k | 0% | Mar 2026 |
|
| Point72 Asset Management | 12k | $40k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 11k | $34k | -60% | Mar 2026 |
|
| Private Advisor | 10k | $34k | 0% | Mar 2026 |
|
| Vanguard Global Advisers | 5.8k | $19k | 100% | Mar 2026 |
|
| EverSource Wealth Advisors | 5.0k | $16k | 0% | Mar 2026 |
|
| Citigroup | 815.00 | $2.7k | 100% | Mar 2026 |
|
| ORG Partners | 450.00 | $3.4k | 0% | Dec 2025 |
|
| Golden State Equity Partners | 450.00 | $1.5k | 100% | Mar 2026 |
|
| Tower Research Capital | 250.00 | $1.9k | -60% | Dec 2025 |
|
| SBI Securities | 185.00 | $607.003500 | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 64.00 | $209.996800 | 113% | Mar 2026 |
|
| Piscataqua Savings Bank | 25.00 | $81.000000 | 0% | Mar 2026 |
|
| Motiv8 Investments | 10.00 | $0 | 100% | Dec 2025 |
|
| Cassaday & Co Wealth Management | 10.00 | $33.000000 | 100% | Mar 2026 |
|
| Albion Financial Group | 7.00 | $22.999900 | 0% | Mar 2026 |
|
| Federation des caisses Desjardins du Quebec | 1.00 | $3.000000 | 100% | Mar 2026 |
|
| Global Retirement Partners | 1.00 | $8.000000 | 0% | Dec 2025 |
|
| Farther Finance Advisors | 1.00 | $3.000000 | 100% | Mar 2026 |
|
| Caitong International Asset Management | 1.00 | $3.000000 | 100% | Mar 2026 |
|
Who sold out of Oncocyte Corporation?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Jane Street | Dec 2025 | 43k | $319k |
| Goldman Sachs Group | Dec 2025 | 24k | $180k |
| Citadel Advisors | Dec 2025 | 16k | $117k |
| Hudson Bay Capital Management | Dec 2025 | 13k | $98k |
| Jpmorgan Chase & Co | Sep 2025 | 154.00 | $511.002800 |